To evaluate the use of Purabond® in transoral resections of primary oral or oropharyngeal lesions for diagnostic and therapeutic procedures. Patients will be enrolled and randomised to either have PuraBond® applied to the surgical field or not intra operatively. The primary outcome measure will assess if this intervention significantly reduces acute pain during the 30 day post-operative period alongside other post-operative complication rates and recovery outcomes.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change From Baseline in Cumulative Pain on the Visual Analogue Scale (VAS) at Postoperative Week 1
Timeframe: Baseline and day 7
Change From Baseline in Cumulative Pain on the Visual Analogue Scale (VAS) at Postoperative Week 2
Timeframe: Baseline and day 14
Change From Baseline in Cumulative Pain on the Visual Analogue Scale (VAS) at Postoperative Day 30
Timeframe: Baseline and day 30
Change From Baseline in Pain on the Visual Analogue Scale (VAS) at Day 1
Timeframe: Baseline and day 1
Change From Baseline in Pain on the Visual Analogue Scale (VAS) at Day 2
Timeframe: Baseline and day 2
Change From Baseline in Pain on the Visual Analogue Scale (VAS) at Day 4
Timeframe: Baseline and day 4
Change From Baseline in Pain on the Visual Analogue Scale (VAS) at Day 7
Timeframe: Baseline and day 7
Change From Baseline in Pain on the Visual Analogue Scale (VAS) at Day 14
Timeframe: Baseline and day 14
Change From Baseline in Pain on the Visual Analogue Scale (VAS) at Day 30
Timeframe: Baseline and day 30